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Abstract
Background: An earlier case-control study from Western Australia reported a protective effect
of maternal folic acid supplementation during pregnancy on the risk of childhood acute
lymphoblastic leukaemia (ALL). The present study tested that association.
Methods: A national case-control study was conducted in New Zealand. The mothers of 97
children with ALL and of 303 controls were asked about vitamin and mineral supplements taken
during pregnancy.
Results: There was no association between reported folate intake during pregnancy and childhood
ALL (adjusted odds ratio (OR) 1.1, 95% confidence interval (CI) 0.5–2.7). Combining our results
with the study from Western Australia and another study from Québec in a meta-analysis gave a
summary OR of 0.9 (95% CI 0.8–1.1).
Conclusion:  Our own study, of similar size to the Australian study, does not support the
hypothesis of a protective effect of folate on childhood ALL. Neither do the findings of the meta-
analysis.
Background
Despite decades of research, the aetiology of childhood
leukaemia remains enigmatic. There have been clear
increases in the incidence rates of childhood leukaemia in
New Zealand and other countries, highlighting the aetio-
logical importance of unknown environmental factors
[1]. There is a natural appeal to any evidence suggesting
that a modifiable factor could be protective. In 2001, a
case-control study from Western Australia showed a pro-
tective effect of maternal folate supplements (taken in
pregnancy) on the risk of childhood common acute lym-
phoblastic leukaemia (ALL) [2]. The odds ratio (OR) for
iron or folate supplementation was 0.4 (95% confidence
interval (CI) 0.2–0.7). Most mothers used folate in con-
junction with iron, so the authors could not report sepa-
rate findings for folate alone. They suggested that the
effect was likely to be from the folate or from iron and
folate together.
A case-control study from northern California looked at
maternal diet and vitamin supplements in the twelve
months before pregnancy, and found no statistically sig-
nificant association between childhood ALL and any vita-
min or iron supplements [3]. Total dietary folic acid,
presumably including supplements, gave an odds ratio of
0.8 (95% CI 0.3–1.8). However use of folic acid supple-
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ments specifically was not reported, so the Californian
findings are not directly comparable with those from Aus-
tralia. In a large case-control study of childhood ALL from
Québec, Shaw and colleagues looked at maternal use of
vitamins and minerals during pregnancy [4]. They found
no association between use of supplements that con-
tained folic acid (alone or in combination) and child-
hood ALL in the offspring (OR 1.0, 95% CI 0.8–1.2).
In this paper we have tested the hypothesis raised by the
Australian study that folate supplementation in preg-
nancy reduces the risk of childhood ALL. We have also
assessed the effects of iron and multivitamin supple-
ments. In addition to looking at maternal pregnancy con-
sumption, we have looked at supplement use by the child.
Methods
In the 1990s, we interviewed families for a case-control
study of childhood cancers in New Zealand to test
hypotheses related to infections and vaccinations, electro-
magnetic fields, chemicals and other exposures [5,6]. The
study included questions for mothers about the use of
vitamins and other supplements.
The detailed methods of this population-based national
case-control study are described elsewhere [5,6]. Briefly,
the cases were ascertained from the National Cancer Reg-
ister and other sources. The whole study included children
diagnosed with any type of cancer at ages 0–14 during
1990–93. The 344 eligible cases were born and resident in
NZ. They had been diagnosed with cancer of any kind;
including 131 children with leukaemias and 213 with
solid cancers. The mothers of 303 cases (88 per cent) gave
interviews. Restricting to ALL, there were 104 eligible cases
and 97 mothers (93 per cent) gave interviews.
The controls were selected at random from birth records,
while matching 1:1 to cases on age and sex. Of 303 eligi-
ble first choice controls, the mothers of 209 (69%) con-
sented and took part. Replacement controls were selected
for the rest [5,6].
Home interviews were conducted using structured ques-
tionnaires. Mothers were asked "Did you take any vitamins
or mineral supplements during your pregnancy, in the 3 months
before, or while breastfeeding? Include iron or folate and any
others." Those who replied 'yes' were then asked "What was
the name of the vitamin or mineral (please be specific)?" They
were then asked to specify their usage of each vitamin/
mineral in each of the periods of interest. Information was
also collected on vitamin and mineral supplementation of
the child. Mothers were asked: "Did {child's name} take any
vitamins or mineral supplements for five days or more (or on 5
or more occasions) at any time prior to ...../...../..... {reference
date}?" For each case, the reference date was their diagno-
sis date. For each control it was the date on which they
were the same age (in days) as their matched case was at
diagnosis. If the mother said 'yes' to the question about
supplement use by the child, then she was asked to specify
the name of each vitamin or mineral supplement taken,
and to answer questions about the timing, duration and
frequency of its use. We excluded supplements taken by
the child within 6 months of the diagnosis/reference date
because they may have been taken as a consequence of
early disease and were not likely to be related to causation.
Folate could be taken on its own, or more usually in com-
bination with iron or as part of a multivitamin prepara-
tion. Separate analyses were attempted for 'any folate'
(incorporating all of the aforementioned), and for 'folate
only' if numbers permitted.
The main analysis involved the cases of ALL and controls,
and was by unconditional logistic regression. This
unmatched analysis was based on the cases and all the
available controls, to increase the statistical power (97
ALL cases, 303 controls). In breaking the matching, we
always adjusted for the matching factors (age and sex).
Possible confounders were identified on the basis of plau-
sibility and a 10% change in estimate. Such a strategy was
used for other aspects of the study [5,6]. Following this
strategy, the mother's marital status and education were
adjusted for in addition to the matching factors. Matched
analyses were also conducted to check whether they
would have made any difference to the results.
Results
Folic acid supplements were taken in pregnancy by 9% of
case mothers and 9% of control mothers. Among the con-
trols, only one of the 27 women who took folate (Table 1)
did not take iron, whereas 116 of the 142 who took iron
did not take folate. Among the cases, two of the eight
women who took folate did not take iron, and 38 of the
44 who took iron (Table 1) did not take folate. The corre-
lation coefficient between iron and folate use in the moth-
ers was 0.27, and in the children it was 0.93. There was no
indication from either the matched or unmatched analy-
ses of an interaction between iron and folate supplemen-
tation. Only 3 case mothers and 14 control mothers took
multivitamins. All of those were recorded as having taken
folate and iron. All of the multivitamins that were taken
included folate and iron. Among the first choice controls,
9.8% of mothers took folate supplements, whereas in the
second or later choice controls this was 7.7%; the differ-
ence was not significant (p = 0.56).
The unmatched analyses showed no statistically signifi-
cant association between the mother's use of folate (any,
with or without iron) in pregnancy and the risk of child-
hood acute lymphoblastic leukaemia (Table 1, OR 1.1,BMC Public Health 2007, 7:136 http://www.biomedcentral.com/1471-2458/7/136
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95% CI 0.5–2.7). There were also no associations relating
to intake during the other periods studied (3 months pre-
pregnancy and while breastfeeding). There are small num-
bers in some categories and the estimates are imprecise.
Folate 'only' (without iron) could not be examined
because of the low prevalence of this exposure; this was
also the case in the study by Thompson and colleagues.
When we restricted the diagnosis to B-precursor ALL, there
was some loss of precision, but no material change to the
findings. Matched analyses also showed no statistically
significant relationships, but they produced wider confi-
dence intervals due to a loss of power (conditional logistic
regression, data not shown).
There were no statistically significant findings relating to
the mother's use of iron (without folate) or multivitamins
(Table 1). The odds ratios for iron were above 1.0, and
those for multivitamins were below 1.0. When the regres-
sions for folate were adjusted for iron and vice versa the
results did not change. No associations were found
between the child's use of folate, iron or multivitamins
and the risk of ALL (Table 1).
Discussion
Since the report by Thompson and colleagues [2], several
studies have investigated the risk of paediatric ALL in rela-
tion to variant forms of the methylenetetrahydrofolate
reductase (MTHFR) gene. Not all these studies have been
consistent. Some have suggested a decreased risk of ALL
for some patients with particular allelic variants [7], while
others have not [8,9].
The authors of the case-control study from California
reported no association between maternal pre-pregnancy
dietary folate and childhood ALL [3]. They also found no
association for iron. A subsequent paper from that study,
with an expanded number of cases and controls, reported
a decreased risk of ALL in relation to use of iron supple-
ments by mothers in the period 3 months before preg-
nancy, during pregnancy or while breastfeeding, with an
overall odds ratio of 0.7 (0.5–0.9) [10]. Although we
found no associations with iron use (Table 1), several
other studies have reported varying findings [10].
Shaw et al. have reported findings from their large Cana-
dian case-control study of childhood ALL and use of med-
ications during pregnancy [4]. They included information
about vitamins – those containing folic acid (alone or in
preparations containing other vitamins or minerals) and
other vitamins or minerals. Almost 60 percent of the
mothers in their study used pregnancy supplements that
contained folic acid. They found no association between
Table 1: Acute lymphoblastic leukaemia in relation to intake of vitamin and mineral supplements by the mother during pregnancy, and 
by the child before the reference date. Unmatched analyses
Supplement & details of use Categories No. of cases No. of controls Odds ratio (CI)
Adjusted for age in years and sex 
only
Adjusted for age, sex, and other 
variables *
Mother's use during the pregnancy
Folic acid (any, No 82 268
with or without iron) Yes 8 27 0.9 (0.4–2.2) 1.1 (0.5–2.7)
Iron (any, No 45 151
with or without folic acid) Yes 44 142 1.1 (0.7–1.8) 1.2 (0.7–2.1)
Iron without folic acid No 51 177
Yes 38 116 1.2 (0.7–2.1) 1.3 (0.8–2.3)
Multivitamins No 87 281
Yes 3 14 0.7 (0.2–2.5) 0.8 (0.2–3.1)
Other vitamin or No 78 263
mineral supplements Yes 13 32 1.3 (0.6–2.6) 1.5 (0.7–3.1)
Child's use before the reference date †
Folic acid (any, No 90 288
with or without iron) Yes 6 15 1.2 (0.4–3.2) 1.0 (0.4–2.8)
Iron (any, No 89 286
with or without folic acid) Yes 7 17 1.2 (0.5–3.1) 1.1 (0.4–2.8)
Iron without folic acid No 95 301
Yes 1 2 1.3 (0.1–15.5) 1.6 (0.1–19.3)
Multivitamins No 90 288
Yes 6 15 1.2 (0.4–3.2) 1.0 (0.4–2.8)
Other vitamin or No 82 272
mineral supplements Yes 14 31 1.5 (0.7–3.0) 1.6 (0.8–3.4)
* Adjusted for age, sex, marital status, and mother's education.
† Restricted to child's use of a supplement for 5 or more days, either in a row or separate days. Child's usage in the six months prior to the diagnosis or reference date was 
not counted.BMC Public Health 2007, 7:136 http://www.biomedcentral.com/1471-2458/7/136
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the risk of ALL and maternal use of supplements contain-
ing folic acid (OR 1.0, 95% CI 0.8–1.2), or other vitamins
(OR 1.0, 95% CI 0.7–1.3) [4].
Limitations of our study include its small size (a conse-
quence of the small population of New Zealand), and the
low prevalence of folate supplementation reported by the
mothers of the cases and controls. On its own, our study
cannot exclude a protective association like that indicated
by the Australian study – this is shown quantitatively by
the overlap in the confidence intervals of the two studies.
As in the Australian study, it was not possible to look at
the effect of folate alone (without iron). We also lacked
information on dietary folate. Fortification of foods such
as breakfast cereals began in the mid 1990s, after the data
collection for our study [11]. Folate supplement use in the
periconceptional period was to some extent promoted fol-
lowing the publication of the results of the MRC trial on
folic acid and prevention of neural tube defects in 1991.
However New Zealand did not have a comprehensive
folic acid campaign like that in the UK [12].
Conducting a fixed effects meta-analysis [13] to combine
the Thompson and Shaw studies with our study, the joint
folate analysis gives an OR of 0.9 (95% CI 0.8–1.1). In
other words, there is no association between the risk of
childhood ALL and maternal folate use in pregnancy for
the three studies combined. The heterogeneity test gives I2
= 74% (p = 0.02) because the findings of the Thompson
study differ from the other two.
Several possible biological mechanisms have been sug-
gested for an effect of folate in reducing the risk of cancers.
These relate to alterations in DNA methylation, a role of
folate in DNA repair, methylenetetrahydrofolate reduct-
ase polymorphisms, and other possible mechanisms [14].
Our results did not confirm a protective effect of folate
supplementation in pregnancy on the risk of childhood
ALL. Retrospective cohort or nested case-control studies
could be considered in countries where it is possible to
link cancer registrations with antenatal clinic records. But
these would be limited by the quality of data recorded
about supplement prescribing or usage, and they could
not easily take account of 'over-the-counter' purchasing of
supplements by mothers.
Conclusion
We did not confirm the association found in the Austral-
ian study of a lower risk of ALL related to maternal folic
acid supplementation in pregnancy. Our meta-analysis of
three relevant studies showed no statistically significant
association.
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